Literature DB >> 18305214

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.

Ya-Wei Qiang1, Yu Chen, Owen Stephens, Nathan Brown, Bangzheng Chen, Joshua Epstein, Bart Barlogie, John D Shaughnessy.   

Abstract

Multiple myeloma (MM) is characterized by osteolytic bone lesions (OBL) that arise as a consequence of osteoblast inactivation and osteoclast activation adjacent to tumor foci within bone. Wnt signaling in osteoblasts regulates osteoclastogenesis through the differential activation and inactivation of Receptor Activator of Nuclear factor Kappa B Ligand (RANKL) and osteoprotegerin (OPG), positive and negative regulators of osteoclast differentiation, respectively. We demonstrate here that MM cell-derived DKK1, a soluble inhibitor of canonical Wnt signaling, disrupted Wnt3a-regulated OPG and RANKL expression in osteoblasts. Confirmed in multiple independent assays, we show that pretreatment with rDKK1 completely abolished Wnt3a-induced OPG mRNA and protein production by mouse and human osteoblasts. In addition, we show that Wnt3a-induced OPG expression was diminished in osteoblasts cocultured with a DKK1-expressing MM cell line or primary MM cells. Finally, we show that bone marrow sera from 21 MM patients significantly suppressed Wnt3a-induced OPG expression and enhanced RANKL expression in osteoblasts in a DKK1-dependent manner. These results suggest that DKK1 may play a key role in the development of MM-associated OBL by directly interrupting Wnt-regulated differentiation of osteoblasts and indirectly increasing osteoclastogenesis via a DKK1-mediated increase in RANKL-to-OPG ratios.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18305214      PMCID: PMC2435688          DOI: 10.1182/blood-2008-01-132134

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  53 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  LDL-receptor-related protein 6 is a receptor for Dickkopf proteins.

Authors:  B Mao; W Wu; Y Li; D Hoppe; P Stannek; A Glinka; C Niehrs
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

3.  Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow.

Authors:  A Bafico; G Liu; A Yaniv; A Gazit; S A Aaronson
Journal:  Nat Cell Biol       Date:  2001-07       Impact factor: 28.824

4.  LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.

Authors:  Y Gong; R B Slee; N Fukai; G Rawadi; S Roman-Roman; A M Reginato; H Wang; T Cundy; F H Glorieux; D Lev; M Zacharin; K Oexle; J Marcelino; W Suwairi; S Heeger; G Sabatakos; S Apte; W N Adkins; J Allgrove; M Arslan-Kirchner; J A Batch; P Beighton; G C Black; R G Boles; L M Boon; C Borrone; H G Brunner; G F Carle; B Dallapiccola; A De Paepe; B Floege; M L Halfhide; B Hall; R C Hennekam; T Hirose; A Jans; H Jüppner; C A Kim; K Keppler-Noreuil; A Kohlschuetter; D LaCombe; M Lambert; E Lemyre; T Letteboer; L Peltonen; R S Ramesar; M Romanengo; H Somer; E Steichen-Gersdorf; B Steinmann; B Sullivan; A Superti-Furga; W Swoboda; M J van den Boogaard; W Van Hul; M Vikkula; M Votruba; B Zabel; T Garcia; R Baron; B R Olsen; M L Warman
Journal:  Cell       Date:  2001-11-16       Impact factor: 41.582

5.  Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.

Authors:  Shmuel Yaccoby; Roger N Pearse; Cherie L Johnson; Bart Barlogie; Yongwon Choi; Joshua Epstein
Journal:  Br J Haematol       Date:  2002-02       Impact factor: 6.998

6.  A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait.

Authors:  Randall D Little; John P Carulli; Richard G Del Mastro; Josée Dupuis; Mark Osborne; Colleen Folz; Susan P Manning; Pamela M Swain; Shan-Chuan Zhao; Brenda Eustace; Michelle M Lappe; Lia Spitzer; Susan Zweier; Karen Braunschweiger; Youssef Benchekroun; Xintong Hu; Ronald Adair; Linda Chee; Michael G FitzGerald; Craig Tulig; Anthony Caruso; Nia Tzellas; Alicia Bawa; Barbara Franklin; Shannon McGuire; Xavier Nogues; Gordon Gong; Kristina M Allen; Anthony Anisowicz; Arturo J Morales; Peter T Lomedico; Susan M Recker; Paul Van Eerdewegh; Robert R Recker; Mark L Johnson
Journal:  Am J Hum Genet       Date:  2001-12-03       Impact factor: 11.025

7.  Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment.

Authors:  N Giuliani; R Bataille; C Mancini; M Lazzaretti; S Barillé
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

8.  Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.

Authors:  R N Pearse; E M Sordillo; S Yaccoby; B R Wong; D F Liau; N Colman; J Michaeli; J Epstein; Y Choi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

9.  Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease.

Authors:  C Seidel; Ø Hjertner; N Abildgaard; L Heickendorff; M Hjorth; J Westin; J L Nielsen; H Hjorth-Hansen; A Waage; A Sundan; M Børset
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

10.  Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.

Authors:  B O Oyajobi; D M Anderson; K Traianedes; P J Williams; T Yoneda; G R Mundy
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

View more
  90 in total

Review 1.  Advances in the understanding of myeloma bone disease and tumour growth.

Authors:  Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

Review 2.  Proteasome inhibitors and bone disease.

Authors:  Ya-Wei Qiang; Christoph J Heuck; John D Shaughnessy; Bart Barlogie; Joshua Epstein
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

3.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

Review 4.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

Review 5.  Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.

Authors:  Marina Konopleva; Yoko Tabe; Zhihong Zeng; Michael Andreeff
Journal:  Drug Resist Updat       Date:  2009-07-25       Impact factor: 18.500

6.  Role of decorin in the antimyeloma effects of osteoblasts.

Authors:  Xin Li; Angela Pennisi; Shmuel Yaccoby
Journal:  Blood       Date:  2008-04-24       Impact factor: 22.113

7.  CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

Authors:  Sarah K Johnson; James P Stewart; Rakesh Bam; Pingping Qu; Bart Barlogie; Frits van Rhee; John D Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

8.  Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma.

Authors:  Ya-Wei Qiang; Yu Chen; Nathan Brown; Bo Hu; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Br J Haematol       Date:  2009-11-24       Impact factor: 6.998

9.  The ecology of cancer from an evolutionary game theory perspective.

Authors:  Jorge M Pacheco; Francisco C Santos; David Dingli
Journal:  Interface Focus       Date:  2014-08-06       Impact factor: 3.906

10.  p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction.

Authors:  Jin He; Zhiqiang Liu; Yuhuan Zheng; Jianfei Qian; Haiyan Li; Yong Lu; Jingda Xu; Bangxing Hong; Mingjun Zhang; Pei Lin; Zhen Cai; Robert Z Orlowski; Larry W Kwak; Qing Yi; Jing Yang
Journal:  Cancer Res       Date:  2012-10-11       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.